Recognizing and Managing Malignant Hyperthermia in the ICU
Tranexamic acid is widely recommended to reduce blood loss in major joint arthroplasty, but optimal dosing remains unclear—especially in patients with chronic kidney disease. A new personalized dosing regimen, developed by Qi Yang, PhD, uses pharmacokinetic modeling to tailor treatment based on weight and kidney function.
Anti-fibrinoyltic agent, Tranexamic acid is recommended to be routinely used for major joint arthroplasty to reduce blood loss. Optimal dosing of tranexamic acid is unknown particularly for many of our patients that also have an element of chronic kidney disease.
A new personalized dosing regimen, tailored to individual weight and kidney function, has been developed through pharmacokinetic modeling by Qi Yang, PhD.
Read more in the March 2025 issue of Anesthesiology: doi: 10.1097/ALN.0000000000005397
